Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years of age and older and high-risk individuals aged 12-64 years.

In the APOLLO trial, first-line treatment with anlotinib plus penpulimab improved progression-free survival and overall survival when compared to sorafenib.